We were delighted to take part in the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) Technology Partn3Ring webinar series, where Chloé Prunier, PhD, Senior Scientist & Project Manager at INOVOTION, presented our latest advances in oncology drug testing using the chicken Chorio-Allantoic membrane (CAM) model.

In this session, Chloé introduced our patient-derived organoid–CAM hybrid model, a powerful and ethical in vivo platform that bridges the gap between traditional cell culture and mammalian models. This innovative approach enables:

– Rapid and robust assessment of efficacy, toxicity, angiogenesis, and immune infiltration
– Integration of patient-derived organoids for translational oncology studies
– Support for precision medicine pipelines, from early discovery to mechanism-of-action validation

The CAM assay offers a vascularize and immune-competent environment to evaluate cutting-edge therapeutic modalities – including small molecules, ADCs, RNA-based treatments, CAR-T, and immunotherapies – while contributing to the 3Rs principles (Replacement, Reduction, Refinement) and remaining cost efficient.

We are currently seeking collaborations with pharma, biotech, and academic partners interested in co-developing assays using patient-derived organoids for drug development.

Watch the full replay here: https://lnkd.in/dU2UsrhZ

Let’s build the next generation of translational oncology models together!